The drugmaker is partnering with Oxford to develop the adenovirus vector-based vaccine, ChAdOx1 nCoV-19, which entered a Phase I/II clinical trial of more than 1,100 healthy volunteers in the U.K. late last month. Data could be available next month, the company said.

LEAVE A REPLY

Please enter your comment!
Please enter your name here